Indications for Enhanced External Counterpulsation (EECP)
EECP may be considered for symptom relief in patients with debilitating refractory angina (CCS Class III/IV) who have failed optimal medical therapy and are not candidates for revascularization procedures (CABG or PCI). 1
Primary Indication: Refractory Angina
The most recent and authoritative guideline evidence establishes EECP as a Class IIb recommendation with Level B evidence for patients with chronic coronary syndromes who have exhausted all other options 1. This represents a specific clinical scenario:
Patient Selection Criteria
You should consider EECP when ALL of the following are present:
- Chronic stable angina lasting ≥3 months with documented reversible ischemia
- CCS Class III or IV symptoms (marked limitation or inability to perform ordinary activities)
- Established obstructive coronary artery disease on angiography
- Failed escalating medical therapy including second- and third-line antianginal agents
- Not a candidate for revascularization due to:
- Poor distal coronary targets
- Excessive surgical risk from comorbidities
- Previous failed revascularization attempts
- Patient refusal of invasive procedures
FDA-Approved Indication
EECP received FDA approval in 1995 specifically for patients with CAD and refractory angina pectoris who fail to respond to standard revascularization procedures and aggressive pharmacotherapy 2. The FDA expanded approval in 2002 to include heart failure patients 3.
Treatment Protocol
The standard regimen consists of:
- 35 one-hour sessions administered over 7 weeks (5 days per week)
- Sequential inflation of pneumatic cuffs on calves, lower thighs, and upper thighs during diastole
- Instantaneous deflation during systole
Absolute Contraindications
Do NOT use EECP in patients with:
- Decompensated heart failure
- Severe peripheral artery disease
- Severe aortic regurgitation
- Deep vein thrombosis or active phlebitis
- Severe pulmonary vascular disease
- Irregular heart rhythms (uncontrolled arrhythmias)
Evidence of Efficacy
The 2014 ACC/AHA guidelines note that while EECP shows promise, the evidence base is limited 2. The MUST-EECP trial demonstrated:
- Significant increase in time to 1-mm ST-segment depression (337±18s to 379±18s vs. placebo 326±21s to 330±20s, p=0.01)
- 55% of patients improved from severe angina to no/mild angina
- 52% discontinued nitroglycerin use
- However, 55% experienced adverse events (leg/back pain, skin abrasions) vs. 26% in controls
Secondary Indication: Heart Failure
EECP has been studied in patients with symptomatic heart failure and left ventricular dysfunction (LVEF ≤35%), showing:
- Maintained symptom improvement at 2-year follow-up in 55% of patients
- 83% survival rate at 2 years
- 70% major adverse cardiovascular event-free survival
- 43% had no cardiac hospitalization
However, the evidence for heart failure remains less robust than for refractory angina, and this should be considered an investigational use in most contexts 4.
Important Caveats
The 2019 ESC guidelines place EECP alongside other experimental therapies (coronary sinus reducer, spinal cord stimulation) all with Class IIb recommendations, reflecting the limited quality of evidence 1. The ACC/AHA guidelines emphasize concerns about:
- Lack of long-term outcome data from RCTs
- High heterogeneity in observational studies
- Potential for placebo effects given the intensive treatment regimen
- Significant adverse event rates
EECP should only be offered after exhaustive attempts at medical optimization and revascularization have been documented, and patients should understand this is a symptom-relief strategy without proven mortality benefit 1, 2.